Browsing by Author "Pérez Cruz, Pedro"
Now showing 1 - 20 of 23
Results Per Page
Sort Options
- ItemAdvantages and disadvantages across the life course and health status in old age among women in Chile(2019) Madero Cabib, Ignacio; Azar Denecken, Ariel Ricardo; Pérez Cruz, Pedro
- ItemAre cannabinoids an alternative for cachexia-anorexia syndrome in patients with advanced cancer?(2017) Cabeza, Claudia; Corsi, Oscar; Pérez Cruz, Pedro
- ItemClinical Signs of Impending Death in Cancer Patients(2014) Hui, David; Dos Santos, Renata; Chisholm, Gary B.; Bansal, Swati; Silva, Thiago Buosi; Kilgore, Kelly; Crovador, Camila de Sousa; Yu, Xiaoying; Swart, Michael D.; Pérez Cruz, Pedro
- ItemDecisional control preferences among patients with advanced cancer: An international multicenter cross-sectional survey(2018) Yennurajalingam, Sriram; Rodrigues, Luis Fernando; Shamieh, Omar M.; Tricou, Colombe; Filbet, Marilene; Naing, Kyaw; Ramaswamy, Akhileshwaran; Pérez Cruz, Pedro; Bautista, Mary Jocylyn S.; Bunge, Sofia; Muckaden, Mary Ann; Fakrooden, Sar
- ItemEscalas de Estado Funcional (o performance satus) en Cáncer(2014) Pérez Cruz, Pedro; Acevedo Claros, Francisco Nicolás
- ItemFactors Associated With Attrition in a Multicenter Longitudinal Observational Study of Patients With Advanced Cancer(2018) Pérez Cruz, Pedro; Shamieh, Omar; Paiva, Carlos Eduardo; Kwon, Jung Hye; Muckaden, Mary Ann; Bruera, Eduardo; Hui, David
- ItemInfluencia de los síntomas físicos, y la funcionalidad, en la relación entre la conciencia pronóstica y el malestar emocional, en pacientes con cáncer avanzado(2019) San Martín Frías, María Jesús; Repetto Lisboa, Paula Beatriz; Pérez Cruz, Pedro; Pontificia Universidad Católica de Chile. Escuela de PsicologíaIntroducción: La conciencia pronóstica se entiende como la capacidad de reconocer que la enfermedad terminal no tiene cura e implica un pronóstico de vida acotado. Cerca del 50% de las personas diagnosticadas con una enfermedad terminal no tiene una conciencia pronóstica ajustada a la realidad, lo que tiene implicancias importantes para la calidad de vida de estos pacientes y cercanos. En la literatura se han reportado resultados contradictorios respecto de la relación entre conciencia pronóstica y malestar emocional que podrían explicarse por diferencias culturales, junto con la influencia de variables físicas y funcionales de la persona. Métodos: Los participantes fueron 201 adultos. Un 49,8% eran mujeres, con un promedio de edad de 64,5 años (d.e=14,08, rango= 23-95). Se evaluó la conciencia pronóstica, el malestar emocional, la funcionalidad y los síntomas físicos. Se realizaron una serie de análisis descriptivos y de regresión para evaluar la relación existente entre cada una de las variables del estudio. Resultados: El 48,8% de la muestra no tendría conciencia pronóstica, aquellos con conciencia pronóstica presentaron puntajes más altos en el HADS-D. Ser mujer y presentar más síntomas físicos, se relacionaron con un mayor malestar emocional. Discusión: Existe un porcentaje importante de pacientes que no manifiestan conciencia pronóstica, en porcentajes similares a los descritos en estudios anteriores. La conciencia pronóstica se asocia con mayor malestar emocional, a diferencia de lo descrito en estudios anteriores. Diferencias culturales podrían estar influyendo en estos resultados y que sugieren la necesidad de estudios en otras poblaciones.
- ItemIs acetaminophen beneficial in patients with cancer pain who are on strong opioids? A randomized controlled trial(2023) Leiva, Ofelia; Letelier Saavedra, Luz María; Rojas Orellana, Luis; Viviani García, Paola; Castellano, Joel; González Candia, Antonio Felipe; Pérez Cruz, PedroContextPain is common among cancer patients. The evidence recommends using strong opioids in moderate to severe cancer pain. No conclusive evidence supports the effectiveness of adding acetaminophen to patients with cancer pain who are already using this regime.ObjectiveTo assess the analgesic efficacy of acetaminophen in hospitalized cancer patients with moderate to severe pain receiving strong opioids.MethodsIn this randomized blinded clinical trial, hospitalized cancer patients with moderate or severe acute pain managed with strong opioids were randomized to acetaminophen or placebo. The primary outcome was pain intensity difference between baseline and 48 hours using the Visual Numeric Rating Scales (VNRS). Secondary outcomes included change in morphine equivalent daily dose (MEDD), and patients’ perception of improved pain control.ResultsAmong 112 randomized patients, 56 patients received placebo, 56 acetaminophen. Mean (standard deviation (SD)) decrease in pain intensity (VNRS) at 48 hours were 2.7 (2.5) and 2.3 (2.3), respectively (95% Confidence Interval(CI) [-0.49;1.32];p=0.37). Mean (SD) change in MEDD was 13.9 (33.0) mg/day and 22.4 (57.7), respectively (95% CI [-9.24;26.1];p=0.35). The proportion of patients perceiving pain control improvement after 48 hours was 82% in the placebo and 80% in the acetaminophen arms (p=0.81).ConclusionAmong patients with cancer pain on strong opioid regime, acetaminophen may not improve pain control, or decrease total opioid use. These results add to the current evidence available suggesting not to use acetaminophen as an adjuvant for advanced cancer patients with moderate to severe cancer pain who are on strong opioids.
- ItemIs parenteral hydration beneficial in terminally ill cancer patients?(2018) Canihuante, José; Pérez Cruz, Pedro
- ItemLongitudinal temporal and probabilistic prediction of survival in a cohort of patients with advanced cancer(2014) Pérez Cruz, Pedro; Dos Santos, R.; Silva, T.; Crovador, C.; Nascimento, M.; Hall, S.; Fajardo, J.; Bruera, E.; Hui, D.
- ItemMethylphenidate and/or a nursing telephone intervention for fatigue in patients with advanced cancer : a randomized, placebo-controlled, phase II trial(2013) Bruera, Eduardo; Yennurajalingam, Sririam; Palmer, J. Lynn; Pérez Cruz, Pedro; Frisebee-Hume, Susan; Allo, Julo; Williams, J. L.; Cohen, M. Z.
- ItemMinimal Clinically Important Difference in the Physical, Emotional, and Total Symptom Distress Scores of the Edmonton Symptom Assessment System(2016) Hui, D.; Shamieh, O.; Paiva, C. E.; Khamash, O.; Pérez Cruz, Pedro; Kwon, J. H.; Muckaden, M. A.; Park, M.; Arthur, J.; Bruera, E.
- ItemMinimal clinically important differences in the Edmonton Symptom Assessment Scale in cancer patients : A prospective, multicenter study(2015) Hui, D.; Shamieh, O.; Paiva, C. E.; Pérez Cruz, Pedro; Kwon, J. H.; Muckaden, M. A.; Park, M.; Yennu, S.; Kang, J. H.; Bruera, E.
- ItemObjective burden, caregiver psychological distress, and patient religion and quality of life are associated with high-intensity burden of care among caregivers of advanced cancer patients in a Latino population(2023) Soto Guerrero, Sebastián; Palacios, Josefa; Langer, Paola; Carrasco, Cecilia; Tupper-Satt, Laura; González-Otaíza, Marcela; Rodríguez Núñez, Alfredo; Pérez Cruz, PedroObjectives: Family caregivers (FCs) of cancer patients experience burden of care. The aims of this study are to describe the caregiving phenomenon among FCs of advanced cancer patients in a Latino community and to identify caregiver and atient characteristics associated with high-intensity subjective caregiver burden. Methods: In this cross-sectional study, advanced cancer patient–caregiver dyads assessed at a Palliative Care Unit in Santiago, Chile, enrolled in a longitudinal observational study were included. FCs completed questions to describe the caregiving phenomenon and surveys to assess burden of care, psychological distress, and perception of patients’ symptoms; patients completed surveys to assess physical distress and quality of life (QOL). We explored associations between high-intensity subjective caregiver burden with caregiver and patient variables. Results: Two hundred seven dyads were analyzed. FCs were on average 50 years old and 75% female. Thirty-two percent of FCs experienced high-intensity subjective burden of care. Eighty two percent of FCs took care of the patient daily and 31% took care of the patient alone. In univariate analysis, high-intensity caregiver burden was associated with caregiver depression (59% vs. 27%; p < 0.001), anxiety (86% vs. 67%; p = 0.003), caring for the patient alone (45% vs. 24%; p = 0.002), perception of patient symptom distress, patient religion, and worse patient QOL (mean [standard deviation] 58 [33] vs. 68 [27]; p = 0.03). In multivariate analysis, FC depression (OR [95% confidence interval] 3.07 [1.43–6.60]; p = 0.004), anxiety (3.02 [1.19–7.71]; p = 0.021), caring for the patient alone (2.69 [1.26–5.77]; p = 0.011), caregiver perception of patient’s fatigue (1.26 [1.01–1.58]; p = 0.04), and patient’s religion (3.90 [1.21–12.61]; p = 0.02) were independently associated with caregiver burden. Significance of results: FCs of advanced cancer patients in a Latino community frequently experience high-intensity burden of care and are exposed to measures of objective burden. High-intensity burden is associated with both caregiver and patient factors. Policies should aim to make interventions on patient–caregiver dyads to decrease caregiving burden among Latinos.
- ItemPatient perception of physician compassion after a more optimistic vs a less optimistic message : a randomized control trial(2015) Tanco, Kimberson; Rhondali, Wadih; Pérez Cruz, Pedro; Tanzi, Silvia; Chisholm, Gary B.; Baile, Walter; Frisbee Hume, Susan; Williams, Janet; Masino, Charles; Sisson, Amy; Arthur, Joseph; Bruera, Eduardo; Cantu, Hilda
- ItemPatient-physician communication about code status preferences. A Randomized Controlled Trial(2013) Rhondali, W.; Pérez Cruz, Pedro; Hui, D.; Chisholm, G.; Dalal, S.; Baile, W.; Chittenden, E.; Bruera, E.
- ItemPerception of Curability Among Advanced Cancer Patients : An International Collaborative Study(2018) Yennurajalingam, Sriram; Rodrigues, Luis Fernando; Shamieh, Omar; Tricou, Colombe; Filbet, Marilène; Naing, Kyaw; Ramaswamy, Akhileshwaran; Pérez Cruz, Pedro; Bautista, Mary Jocelyn S.; Bunge, Sofia; Muckaden, Mary Ann; Sewram, Vikash; Fakrooden, Sarah; Noguera-Tejedor, Antonio; Rao, Shobha S.; Liu, Diane; Park, Minjeong; Williams, Janet L.; Lu, Zhanni; Cantu, Hilda; Hui, David; Reddy, Suresh K.; Bruera, Eduardo
- ItemPersonalized symptom goals and response in patients with advanced cancer(2016) Hui, David; Park, Minjeong; Shamieh, Omar; Paiva, Carlos Eduardo; Pérez Cruz, Pedro; Muckaden, Mary Ann; Bruera, Eduardo
- ItemPortafolio en pregrado de Medicina: impacto educacional a 10 años de su implementación(2019) Reyes Placencia, Diego; Isbej Espósito, Lorena Pilar; Uribe Monasterio, Javier; Ruz Laurent, Cristian; Pizarro Rojas, Margarita; Walker Cruchaga María Rosa; Pérez Cruz, Pedro; Maldonado Morgado, Armando; Robles García, Camila; Latorre Selvat, Gonzalo; Ivanovic-Zuvic Seeger, Danisa; Figueroa, Catalina; González, Agustín; Cotoras Viedma, Petre; Núñez Palma, Carolina Verónica; Labarca L., Jaime; Riquelme, Arnoldo
- ItemRandomized double-blind controlled trial to assess the efcacy of intravenous acetaminophen associated with strong opioids in the treatment of acute pain in adult cancer patients: study protocol(2022) Leiva, Ofelia; Castellano, Joel; Letelier Saavedra, Luz María; Rojas Orellana, Luis; Viviani García, Paola; González Candia, Antonio Felipe; Pérez Cruz, PedroBackground: Cancer pain is one of the most frequent and relevant symptoms in cancer patients and impacts on patient’s quality of life. International and local standards recommend as an initial strategy the use of an analgesic scheme composed of strong opioids associated with adjuvants such as acetaminophen, based upon the assumption that combining drugs could have a better analgesic effect, could allow lowering opioid dosing, and could prevent the occurrence of adverse effects of opioids. However, there is uncertainty about the impact of acetaminophen as an adjuvant in patients who use strong opioids for moderate to severe pain management in cancer patients. The aim of this study is to assess the efficacy and safety of intravenous acetaminophen associated with strong opioids in hospitalized adult cancer patients who have moderate to severe cancer-related pain. Methods: We will perform a randomized double-blinded controlled study comparing intravenous acetaminophen 1 g 4 times a day versus placebo for 48 h as an adjuvant to strong opioids. We will assess pain intensity as a primary outcome, using the verbal numerical rating scale (VNRS, I0 to 10 scale with higher scores meaning higher pain intensity), and we will compare the mean difference in pain intensity between baseline and 48 h among the placebo and intervention groups. We estimate that a decrease of 1 point in the VNRS would be clinically significant. Assuming a standard deviation in pain intensity of 1.7 points, an alpha of 0.025, and a power of 0.8, we estimate a sample size of 112 patients, with 56 patients in each arm. Secondary outcomes include the difference in total opioid use between baseline and at 48 h among the groups, and adverse effects such as drowsiness, constipation, nausea, and vomiting would be evaluated. Discussion: The randomized, double-blind, placebo-controlled design is the best strategy to assess the efficacy of acetaminophen as an adjuvant in adult cancer patients with moderate to severe pain who are receiving strong opioids. We expect to contribute to national and international guidelines with these results.